A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors

Chimeric antigen receptor (CAR) T cell immunotherapies hold great promise for cancer treatment, but they are not very effective against solid tumors. Niki Spahich from The Scientist’s Creative Services team spoke with Katie McKenna, postdoctoral fellow in the laboratory of Malcolm Brenner at the Center for Cell and Gene Therapy at Baylor College of Medicine, about her work developing a combination CAR T cell immunotherapy and oncolytic virotherapy to treat solid tumors.

LabTalk is a special edition podcast produced by The Scientist’s Creative Services Team, where we explore topics at the leading edge of innovative research. This episode was sponsored by IsoPlexis.


Katie McKenna, PhD
Postdoctoral Fellow
Center for Cell and Gene Therapy
Baylor College of Medicine
Texas Children’s Hospital
Methodist Hospital



IsoPlexis is a life science technology company that accelerates the development of curative medicines and precision therapeutics. Their award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise therapies. Their integrated systems were named top innovation or design by The Scientist, Fierce, BIG Innovation, Red Dot, and multiple other companies. These systems are used globally to advance the field of single-cell biology as their customers overcome the challenges of complex diseases. Their products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and 45% of comprehensive cancer centers. Visit http://www.isoplexis.com to learn more.

Listen Now


Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this podcast. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these podcasts free of charge for our readers.